• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Richard T. Penson, MD MRCP


  • Penson RT, Huang HQ, Wenzel LB, Monk BJ, Stockman S, Long HJ, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Method M, Michael H, Tewari KS.
    Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
    Lancet Oncol. 2015 Mar;16(3):301-11.
  • Ambrosio AJ, Suzin D, Palmer EL, Penson RT.
    Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer.
    Expert Rev Clin Pharmacol. 2014 Apr 18.
  • Schapira L, Blaszkowsky LS, Cashavelly BJ, Kim CY, Riley JP, Wold MC, Ryan DP, Penson RT.
    Caring for One of Our Own.
    Oncologist. 2014 Apr 10.
  • George S, Feng Y, Manola J, Nucci MR, Butrynski JE, Morgan JA, Ramaiya N, Quek R, Penson RT, Wagner AJ, Harmon D, Demetri GD, Krasner C.
    Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.
    Cancer. 2014 Mar 1;120(5):738-43.
  • Tewari KS, Sill MW, Long HJ, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ.
    Improved survival with bevacizumab in advanced cervical cancer.
    N Engl J Med. 2014 Feb 20;370(8):734-43.
  • Peterson VM, Castro CM, Chung J, Miller NC, Ullal AV, Castano MD, Penson RT, Lee H, Birrer MJ, Weissleder R.
    Ascites analysis by a microfluidic chip allows tumor-cell profiling.
    Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):E4978-86.
  • Naumann RW, Coleman RL, Burger RA, Sausville EA, Kutarska E, Ghamande SA, Gabrail NY, Depasquale SE, Nowara E, Gilbert L, Gersh RH, Teneriello MG, Harb WA, Konstantinopoulos PA, Penson RT, Symanowski JT, Lovejoy CD, Leamon CP, Morgenstern DE, Messmann RA.
    PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer.
    J Clin Oncol. 2013 Dec 10;31(35):4400-6.
  • Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M.
    Ovarian cancer, version 2.2013.
    J Natl Compr Canc Netw. 2013 Oct 1;11(10):1199-209.
  • Penson RT, Goodman A, Growdon WB, Borger DR, Lee SI, Oliva E.
    Case records of the Massachusetts General Hospital. Case 14-2013. A 70-year-old woman with vaginal bleeding.
    N Engl J Med. 2013 May 9;368(19):1827-35.
  • Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA.
    Ovarian Cancer, Version 3.2012.
    J Natl Compr Canc Netw. 2012 Nov 1;10(11):1339-1349.
  • Campos SM, Penson RT, Matulonis U, Horowitz NS, Whalen C, Pereira L, Tyburski K, Roche M, Szymonifka J, Berlin S.
    A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.
    Gynecol Oncol. 2012 Aug 9.
  • Dizon DS, Damstrup L, Finkler NJ, Lassen U, Celano P, Glasspool R, Crowley E, Lichenstein HS, Knoblach P, Penson RT.
    Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer.
    Int J Gynecol Cancer. 2012 Jul;22(6):979-86.
  • Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ.
    A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.
    Gynecol Oncol. 2011 Jan 26.
  • Morgan RJ, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL.
    Epithelial ovarian cancer.
    J Natl Compr Canc Netw. 2011 Jan;9(1):82-113.
  • Kornblith AB, Mirabeau-Beale K, Lee H, Goodman AK, Penson RT, Pereira L, Matulonis UA.
    Long-term adjustment of survivors of ovarian cancer treated for advanced-stage disease.
    J Psychosoc Oncol. 2010 Sep;28(5):451-69.
  • Penson RT, Schapira L, Mack S, Stanzler M, Lynch TJ.
    Connection: schwartz center rounds at massachusetts general hospital cancer center.
    Oncologist. 2010;15(7):760-4.
  • Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N, Lu K, Schmutzler RK, Matulonis U, Wickens M, Tutt A.
    Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
    Lancet. 2010 Jul 24;376(9737):245-51.
  • Dean-Clower E, Doherty-Gilman AM, Keshaviah A, Baker F, Kaw C, Lu W, Manola J, Penson RT, Matulonis UA, Rosenthal DS.
    Acupuncture as Palliative Therapy for Physical Symptoms and Quality of Life for Advanced Cancer Patients.
    Integr Cancer Ther. 2010 Jun;9(2):158-67.
  • Young RH, Goodman A, Penson RT, Russell AH, Uppot RN, Tambouret RH.
    Case records of the Massachusetts General Hospital. Case 8-2010. A 22-year-old woman with hypercalcemia and a pelvic mass.
    N Engl J Med. 2010 Mar 18;362(11):1031-40.
  • Robinson ES, Matulonis UA, Ivy P, Berlin ST, Tyburski K, Penson RT, Humphreys BD.
    Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.
    Clin J Am Soc Nephrol. 2010 Mar;5(3):477-83.
  • Roche MR, Rudd PJ, Krasner CN, Matulonis UA, Berlin ST, Lee H, Silver M, Tran CD, Seiden MV, Penson RT.
    Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors.
    Gynecol Oncol. 2010 Feb;116(2):168-72.
  • Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM.
    Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
    J Clin Oncol. 2010 Jan 1;28(1):154-9.
  • Na YJ, Farley J, Zeh A, del Carmen M, Penson R, Birrer MJ.
    Ovarian cancer: markers of response.
    Int J Gynecol Cancer. 2009 Dec;19 Suppl 2:S21-9. Review.
  • Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT.
    Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
    J Clin Oncol. 2009 Nov 20;27(33):5601-6.
  • Audeh MW, Penson RT.
    Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer.
    J Clin Oncol.(27).
  • Lu W, Matulonis UA, Doherty-Gilman A, Lee H, Dean-Clower E, Rosulek A, Gibson C, Goodman A, Davis RB, Buring JE, Wayne PM, Rosenthal DS, Penson RT.
    Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial.
    J Altern Complement Med. 2009 Jul;15(7):745-53.
  • Mirabeau-Beale KL,Kornblith AB,Penson RT,Lee H,Goodman A,Campos SM,Duska L,Pereira L,Bryan J,Matulonis UA.
    Comparison of the quality of life of early and advanced stage ovarian cancer survivors.
    Gynecol Oncol. 2009 Aug;114(2):353-9.
  • Hesterberg PE, Banerji A, Oren E, Penson RT, Krasner CN, Seiden MV, Wong JT.
    Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
    J Allergy Clin Immunol. 2009 Jun;123(6):1262-7.e1.
  • Koulouris CR,Penson RT.
    Ovarian stromal and germ cell tumors.
    Semin Oncol. 2009 Apr;36(2):126-36. Review.
  • Matulonis UA, Kornblith A, Lee H, Bryan J, Gibson C, Wells C, Lee J, Sullivan L, Penson R.
    Long-term adjustment of early-stage ovarian cancer survivors.
    Int J Gynecol Cancer.;18(6):1183-93.
  • Penson RT.
    Sugar fuels cancer.
    Cancer. 2009 Mar 1;115(5):918-21.
  • Wenzel L, Penson RT, Carter J, Chase D, Cella D.
    Quality of Life Issues in Gynecologic Oncology.
    Principles and Practice of Gynecologic Oncology, Fifth Edition..
  • Matulonis UA,Krag KJ,Krasner CN,Atkinson T,Horowitz NS,Lee H,Penson RT.
    Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Mullerian tumors.
    Gynecol Oncol. 2009 Feb;112(2):394-9.
  • Matulonis UA,Horowitz NS,Campos SM,Lee H,Lee J,Krasner CN,Berlin S,Roche MR,Duska LR,Pereira L,Kendall D,Penson RT.
    Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    J Clin Oncol. 2008 Dec 10;26(35):5761-6.
  • Rauh-Hain JA, Penson RT.
    Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma.
    Int J Gynecol Cancer.;18(5):934-6.
  • Olawaiye AB,Morgan JA,Goodman A,Fuller AF Jr,Penson RT.
    Epithelioid angiosarcoma of the uterus: a review of management.
    Arch Gynecol Obstet. 2008 Nov;278(5):401-4. Review.
  • Penson RT.
    Cycles within cycles.
  • Penson RT.
    Ovarian Cancer.
    Harrison's Manual of Oncology, Bruce A. Chabner, Thomas J. Lynch, Dan L. Longo (eds). ..
  • Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, Douglas J, Burger RA, Armstrong D, Wenham R, McGuire W.
    Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
    J Clin Oncol. 2007 Nov 20;25(33):5180-6.
  • Abrams AN, Hazen EP, Penson RT.
    Psychosocial issues in adolescents with cancer.
    Cancer Treat Rev. 2007 Nov;33(7):622-30. Review.
  • Penson RT, Gu F, Harris S, Thiel MM, Lawton N, Fuller AF Jr, Lynch TJ Jr.
    Oncologist. 2007 Sep;12(9):1105-13. Review.
  • Penson RT, Joel SP, Gloyne A, Clark S, Slevin ML.
    Morphine analgesia in cancer pain: role of the glucuronides.
    J Opioid Manag. 2005 May-Jun;1(2):83-90.
  • Penson RT, Wenzel LB, Vergote I, Cella D.
    Quality of life considerations in gynecologic cancer.
    Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S247-57. Review.
  • Matulonis UA, Campos S, Krasner CN, Duska LR, Penson RT, Falke R, Roche M, Smith LM, Lee H, Seiden MV, ,.
    Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced mllerian malignancies: The modified triple doublet regimen.
    Gynecol Oncol. 2006 Nov;103(2):575-80.
  • Matulonis UA, Campos S, Duska L, Krasner CN, Atkinson T, Penson RT, Seiden MV, Verrill C, Fuller AF, Goodman A,.
    Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer.
    Gynecol Oncol. 2006 Oct;103(1):160-4.
  • Abel GA, Penson RT, Joffe S, Schapira L, Chabner BA, Lynch TJ.
    Direct-to-consumer advertising in oncology.
    Oncologist. 2006 Feb;11(2):217-26.
  • Matulonis UA, Seiden MV, Roche M, Krasner C, Fuller AF, Atkinson T, Kornblith A, Penson R.
    Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
    J Pain Symptom Manage. 2005 Dec;30(6):563-9.
  • Penson RT, Campos SM, Seiden MV, Krasner C, Fuller AF, Goodman A, Roche M, Willman A, Muzikansky A, Matulonis UA,.
    A phase II study of fixed dose rate gemcitabine in patients with relapsed mllerian tumors.
    Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1035-41.
  • Seiden MV, Gordon AN, Bodurka DC, Matulonis UA, Penson RT, Reed E, Alberts DS, Weems G, Cullen M, McGuire WP.
    A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer.
    Gynecol Oncol. 2006 Apr;101(1):55-61.
  • Penson RT, Seiden MV.
    Topotecan: weighing in when there are many options.
    Oncologist. 2005 Oct;10(9):698-700.
  • Penson RT, Partridge RA, Rudd P, Seiden MV, Nelson JE, Chabner BA, Lynch TJ.
    Laughter: the best medicine?.
    Oncologist. 2005 Sep;10(8):651-60.
  • Penson RT, Seiden MV, Matulonis UA, Appleman LJ, Fuller AF, Goodman A, Campos SM, Clark JW, Roche M, Eder JP.
    A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours.
    Br J Cancer. 2005 Jul 11;93(1):54-9.
  • Wolpin BM, Chabner BA, Lynch TJ, Penson RT.
    Learning to cope: how far is too close?.
    Oncologist. 2005 Jun-Jul;10(6):449-56.
  • Penson RT, Partridge RA, Shah MA, Giansiracusa D, Chabner BA, Lynch TJ.
    Fear of death.
    Oncologist. 2005 Feb;10(2):160-9.
  • Lee MS, Gupta N, Penson RT, Loewenstein J, Wepner MS, Seiden MV, Milam AH.
    Cone damage in patients receiving high-dose irofulven treatment.
    Arch Ophthalmol. 2005 Jan;123(1):29-34.
  • Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA.
    A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.
    Gynecol Oncol. 2004 Dec;95(3):624-31.
  • Penson RT, Dignan F, Seiden MV, Lee H, Gallagher CJ, Matulonis UA, Olson K, Gibbens I, Gore ME.
    Attitudes to chemotherapy in patients with ovarian cancer.
    Gynecol Oncol. 2004 Aug;94(2):427-35.
  • Penson RT, Seiden MV, Goodman A, Fuller AF, Berkowitz RS, Matulonis UA, Krasner C, Lee H, Atkinson T, Campos SM,.
    Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with mllerian malignancies.
    Gynecol Oncol. 2004 Jun;93(3):702-7.
  • Penson RT, Daniels KJ, Lynch TJ.
    Too old to care?.
    Oncologist. 2004;9(3):343-52.
  • Penson RT, Amrein PC.
    Faith and freedom: leukemia in Jehovah Witness minors.
    Onkologie. 2004 Apr;27(2):126-8.
  • Nouriani M, Bahador A, Berek JS, Cheng JP, Chi DS, Cliby WA, Del Priore G, Dodson MK, Duggan BD, Gershenson DM, Lentz SE, Penson RT, Robinson WR, Rodriguez M, Roman LD, Yu MC, Zempolich K, Dubeau L.
    Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy.
    Clin Cancer Res. 2004 Apr 15;10(8):2681-6.
  • Penson RT, Talsania SH, Chabner BA, Lynch TJ.
    Help me help you: support groups in cancer therapy.
    Oncologist. 2004;9(2):217-25.
  • Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF, Goodman A, Seiden MV.
    Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples.
    Gynecol Oncol. 2004 Apr;93(1):98-106.
  • del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, Duska LR, Penson R, Campos S, Roche M, Seiden MV.
    Phase II trial of anastrozole in women with asymptomatic mllerian cancer.
    Gynecol Oncol. 2003 Dec;91(3):596-602.
  • Dias L, Chabner BA, Lynch TJ, Penson RT.
    Breaking bad news: a patient's perspective.
    Oncologist. 2003;8(6):587-96.
  • Penson RT, Fergus LA, Haston RJ, Clark JR, Demotses A, O'Connell JJ, Chabner BA, Lynch TJ.
    The Kenneth B. Schwartz Center at Massachusetts General Hospital hematology-oncology department: hope for the homeless.
    Oncologist. 2003;8(5):488-95.
  • Campos SM, Matulonis UA, Penson RT, Lee H, Berkowitz RS, Duska LR, Fuller AF, Wilson KS, Puchalski TA, Supko JG, Seiden MV.
    Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Mllerian tumors.
    Gynecol Oncol. 2003 Sep;90(3):610-8.
  • Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, Seiden MV.
    Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines.
    Clin Cancer Res. 2003 Jul;9(7):2778-85.
  • Penson RT, Nunn C, Younger J, Schaeffer NJ, Chabner BA, Fricchione GL, Quinn TE, Lynch TJ.
    Trust violated: analgesics for addicts.
    Oncologist. 2003;8(2):199-209.
  • Lamendola DE, Duan Z, Penson RT, Oliva E, Seiden MV.
    beta tubulin mutations are rare in human ovarian carcinoma.
    Anticancer Res. 2003 Jan-Feb;23(1B):681-6.
  • Knuti KA, Wharton RH, Wharton KL, Chabner BA, Lynch TJ, Penson RT.
    Living as a cancer surpriser: a doctor tells his story.
    Oncologist. 2003;8(1):108-22.
  • Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV.
    Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation.
    Curr Cancer Drug Targets. 2003 Feb;3(1):1-19.
  • Penson RT, Benson RC, Parles K, Chabner BA, Lynch TJ.
    Virtual connections: Internet health care.
    Oncologist. 2002;7(6):555-68.
  • Knuti KA, Amrein PC, Chabner BA, Lynch TJ, Penson RT.
    Faith, identity, and leukemia: when blood products are not an option.
    Oncologist. 2002;7(4):371-80.
  • Duan Z, Lamendola DE, Yusuf RZ, Penson RT, Preffer FI, Seiden MV.
    Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype.
    Anticancer Res. 2002 Jul-Aug;22(4):1933-41.
  • Penson RT, Green KM, Chabner BA, Lynch TJ.
    When does the responsibility of our care end: bereavement.
    Oncologist. 2002;7(3):251-8.
  • Duska LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF.
    Paclitaxel and platinum chemotherapy for malignant mixed mllerian tumors of the ovary.
    Gynecol Oncol. 2002 Jun;85(3):459-63.
  • Duan Z, Lamendola DE, Penson RT, Kronish KM, Seiden MV.
    Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells.
    Cytokine. 2002 Mar 7;17(5):234-42.
  • Penson RT, Joel SP, Roberts M, Gloyne A, Beckwith S, Slevin ML.
    The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide.
    Br J Clin Pharmacol. 2002 Apr;53(4):347-54.
  • Penson RT, Rauch PK, McAfee SL, Cashavelly BJ, Clair-Hayes K, Dahlin C, Green KM, Chabner BA, Lynch TJ.
    Between parent and child: negotiating cancer treatment in adolescents.
    Oncologist. 2002;7(2):154-62.
  • Penson RT, Joel SP, Clark S, Gloyne A, Slevin ML.
    Limited phase I study of morphine-3-glucuronide.
    J Pharm Sci. 2001 Nov;90(11):1810-6.
  • Penson RT, Castro CM, Seiden MV, Chabner BA, Lynch TJ.
    Complementary, alternative, integrative, or unconventional medicine?.
    Oncologist. 2001;6(5):463-73.
  • Penson RT, Supko JG, Seiden MV, Fuller AF, Berkowitz RS, Goodman A, Campos SM, MacNeill KM, Cook S, Matulonis UA.
    A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Mllerian tumors.
    Cancer. 2001 Sep 1;92(5):1156-67.
  • Penson RT, Yusuf RZ, Chabner BA, Lafrancesca JP, McElhinny M, Axelrad AS, Lynch TJ.
    Losing God.
    Oncologist. 2001;6(3):286-97.
  • Penson RT, Fuller AF.
    Nodal metastasis is highly consistent in squamous cell carcinoma of the vulva.
    J Clin Oncol. 2001 May 15;19(10):2767-8.
  • Campos SM, Penson RT, Mays AR, Berkowitz RS, Fuller AF, Goodman A, Matulonis UA, Muzikansky A, Seiden MV.
    The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.
    Gynecol Oncol. 2001 May;81(2):206-12.
  • Penson RT, Seiden MV, Chabner BA, Lynch TJ.
    Caring for colleagues.
    Oncologist. 2001;6(2):197-204.
  • Penson RT, Fuller AF.
    Nodal metastasis is highly consistent in squamous cell carcinoma of the vulva.
    J Clin Oncol. 2001 Apr 15;19(8):2364-5.
  • Feller AJ, Duan Z, Penson R, Toh HC, Seiden MV.
    TRAG-3, a novel cancer/testis antigen, is overexpressed in the majority of melanoma cell lines and malignant melanoma.
    Anticancer Res. 2000 Nov-Dec;20(6B):4147-51.
  • Penson RT, Joel SP, Bakhshi K, Clark SJ, Langford RM, Slevin ML.
    Randomized placebo-controlled trial of the activity of the morphine glucuronides.
    Clin Pharmacol Ther. 2000 Dec;68(6):667-76.
  • Penson RT, Svendsen SS, Chabner BA, Lynch TJ, Levinson W.
    Medical mistakes: a workshop on personal perspectives.
    Oncologist. 2001;6(1):92-9.
  • Mulatero CW, Penson RT, Papamichael D, Gower NH, Evans M, Rudd RM.
    A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma.
    Lung Cancer. 2001 Jan;31(1):67-72.
  • Penson RT, Dignan FL, Canellos GP, Picard CL, Lynch TJ.
    Burnout: caring for the caregivers.
    Oncologist. 2000;5(5):425-34.
  • Penson RT, Gallagher J, Gioiella ME, Wallace M, Borden K, Duska LA, Talcott JA, McGovern FJ, Appleman LJ, Chabner BA, Lynch TJ.
    Sexuality and cancer: conversation comfort zone.
    Oncologist. 2000;5(4):336-44.
  • Penson RT, Seiden MV, Shannon KM, Lubratovich ML, Roche M, Chabner BA, Lynch TJ.
    Communicating genetic risk: pros, cons, and counsel.
    Oncologist. 2000;5(2):152-61.
  • Cook S, Penson R, Duska L, Nikrui N, Goodman A, Fuller A, Seiden M.
    Efficacy and hematologic toxicity of salvage chemotherapy following stem cell-supported high-dose chemotherapy in women with recurrent ovarian cancer.
    Gynecol Oncol. 2000 Apr;77(1):48-54.
  • Krakauer EL, Penson RT, Truog RD, King LA, Chabner BA, Lynch TJ.
    Sedation for intractable distress of a dying patient: acute palliative care and the principle of double effect.
    Oncologist. 2000;5(1):53-62.
  • Ryan DP, Penson RT, Ahmed S, Chabner BA, Lynch TJ.
    Reality testing in cancer treatment: the phase I trial of endostatin.
    Oncologist. 1999;4(6):501-8.
  • Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV.
    Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.
    Clin Cancer Res. 1999 Nov;5(11):3445-53.
  • Goodman A, Penson RT, Blatman R, McIntyre J, Gioiella ME, Chabner BA, Lynch TJ.
    A staff dialogue on a socially distanced patient: psychosocial issues faced by patients, their families, and caregivers.
    Oncologist. 1999;4(5):417-24.
  • Penson RT, Skates SJ, Fuller AJ, Seiden MV.
    Clinical course of stage IV epithelial ovarian cancer.
    J Clin Oncol. 1999 Oct;17(10):3361-2.
  • Penson RT, Seiden MV.
    Progress in gynecologic oncology.
    Oncologist. 1999;4(4):293-8.
  • O'Shea EM, Penson RT, Stern TA, Younger J, Chabner BA, Lynch TJ.
    A staff dialogue on do not resuscitate orders: psychosocial issues faced by patients, their families, and caregivers.
    Oncologist. 1999;4(3):256-62.
  • Lintz KC, Penson RT, Chabner BA, Mack S, Lynch TJ.
    Schwartz Center Rounds. A Staff Dialogue on Phase I Trials: Psychosocial Issues Faced by Patients, Their Families, and Caregivers.
    Oncologist. 1998;3(5):357-364.
  • Lintz KC, Penson RT, Chabner BA, Lynch TJ.
    Schwartz Center Rounds. A Staff Dialogue on Caring for an Intensely Spiritual Patient: Psychosocial Issues Faced By Patients, Their Families, and Caregivers.
    Oncologist. 1998;3(6):439-445.
  • O'Shea EM, Lintz KC, Penson RT, Seiden MV, Chabner BA, Lynch TJ.
    A staff dialogue on caring for a cancer patient who commits suicide: psychosocial issues faced by patients, their families, and caregivers.
    Oncologist. 1999;4(2):122-7.
  • Lintz KC, Penson RT, Cassem N, Harmon DC, Chabner BA, Lynch TJ.
    A staff dialogue on aggressive palliative treatment demanded by a terminally ill patient: psychosocial issues faced by patients, their families, and caregivers.
    Oncologist. 1999;4(1):70-6.
  • Papamichael D, Seymour MT, Penson RT, Wilson P, Gallagher CJ, Besser GM, Slevin ML.
    Double modulation of 5-fluorouracil with interferon alpha-2a and high-dose leucovorin in advanced neuroendocrine tumours.
    Eur J Cancer. 1998 Dec;34(13):2133-4.
  • Penson RT, Shannon KE, Sharpless NE, Seiden MV.
    Ovarian cancer: an update on genetics and therapy.
    Compr Ther. 1998 Oct;24(10):477-87.
  • Penson RT, Rudd RM.
    Poor recruitment to lung cancer trials.
    BMJ. 1997 Mar 29;314(7085):974-5.
  • Penson RT, Rudd RM.
    Commentary: octreotide and hypertrophic pulmonary osteoarthropathy.
    Thorax. 1997 Mar;52(3):297-8.